22 October 2018 | Cape Town | Scientists at the South African Medical Research Council (SAMRC) have received top honours from the National Research Foundation (NRF) for their leadership and excellence in science and research.
The rise of multi-drug resistant bacteria threatens to overturn decades of progress on tuberculosis (TB), experts are warning. Multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains […]
URGENT action, including rapid diagnosis, better access to medication, improved home-based care and more community-stay facilities for patients, is crucial in addressing the rising transmission and […]
Eleven UCT researchers have been selected as finalists for the prestigious NSTF-BHP Billiton Awards for 2013/14. The national awards celebrate outstanding contributions to Science, Engineering, Technology […]
Patients with contagious and highly drug-resistant tuberculosis (TB) are being routinely discharged from hospitals across South Africa, exposing others in their communities to potentially deadly infections, […]
Point-of-care Xpert MTB/RIF tuberculosis testing is associated with more patients getting same-day diagnosis and having same-day treatment initiation but does not result in improved tuberculosis-related morbidity, […]
Splinternuwe masjiene wat vir die eerste keer middelweerstandige tuberkulose (MDR-TB) in staatshospitale kan diagnoseer,isdeurdiedepartementvangesondheid aangekoop. Download article Die Burger, 15 April 2011
Dr Keertan Dheda, Associate Professor of Respiratory Medicine at the University of Cape Town, is the recipient of the 2010 Union Scientific Award, bestowed by the International Union Against Tuberculosis and Lung Disease (IUATLD). The annual global award honours a researcher under the age of 45 who has made an outstanding contribution to the field of tuberculosis and/or lung disease.
In The Lancet today, Keertan Dheda and co-authors present an interesting report about early treatment outcomes of extensively drug-resistant (XDR) tuberculosis (resistant to isoniazid, rifampicin, any […]
Although progress has been made to reduce global incidence of drug-susceptible tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis during the past decade […]